This invention provides a composition of matter comprising a plurality of morphine-6-succinyl-BSA, wherein the average ratio of morphine-6-succinyl moieties to BSA is at least 7.0. This invention also provides a composition of matter comprising a plurality of heroin-6-succinyl-B SA, wherein the average ratio of heroin-6-succinyl moieties to BSA is at least 7.0. This invention further provides a composition of matter comprising a plurality of ethanol-succinyl-B SA, wherein the average ratio of ethanol-succinyl moieties to BSA is at least 7.0. This invention still further provides related pharmaceutical compositions, therapeutic methods, prophylactic methods, synthetic methods, and articles of manufacture.

The present invention provides a group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia.

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Nanoparticle forms of thyroid hormone or thyroid hormone analogs as well as uses thereof are also disclosed.

Described herein are compounds for use in vaccine compositions which contain natural or synthetic carbohydrate antigens. Such vaccines may be highly immunologically active due to the conjugation with an immune-stimulating protein or with a monophosphorylated lipid A derivative, and may be self-adjuvanting due to the presence of a monophosphorylated lipid A derivative. Treatments for cancer and fungal and bacterial infections are described herein.

A formulation of pure dimethoxy curcumin-human serum albumin (DMCHSA) comprising a pure di-methoxy curcumin (DMC) bound to human serum albumin (HSA), wherein molar ratio of DMC to HSA is in the range of 3.0-6.0. Further, there is provided a highly soluble and safe intravenous formulation of pure dimethoxy curcumin-human serum albumin retaining proven biological activities and a process for the preparation thereof. Even further, there is provided a process for preparing formulation of pure dimethoxy curcumin-human serum albumin (DMCHSA) by preferential binding of DMC to HSA, which excludes other curcuminoids such as Demethoxy curcumin (DeMC) and Bidemethoxy curcumin (BiDeMC) present in the added chemical, increasing the purity of 80% DMC in starting raw material to >99% in the product DMCHSA.

The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.

The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent.

Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

The invention relates to a therapeutic combination for use as a medicament, wherein the therapeutic combination comprises: (a) a first pharmaceutical composition comprising a first proteinaceous molecule and at least one saponin covalently bound to said first proteinaceous molecule; and (b) a second pharmaceutical composition comprising a second proteinaceous molecule, comprising an effector moiety, wherein the binding site of the first proteinaceous molecule and the binding site of the second proteinaceous molecule are the same. The invention also relates to the first pharmaceutical composition for use as a medicament. The invention also relates to the first pharmaceutical composition, further comprising the second proteinaceous molecule. The invention also relates to the first pharmaceutical composition, further comprising the second proteinaceous molecule, for use as a medicament. Furthermore, the invention relates to the first pharmaceutical composition, further comprising the second proteinaceous molecule, for use in the treatment or prophylaxis of cancer in a patient in need thereof.

Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.